Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue
November 6, 2025 4:27 PM ESTCoherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $13.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
... More


